BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 36689809)

  • 1. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ensitrelvir as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
    Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
    J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
    Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
    Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites.
    Iketani S; Hong SJ; Sheng J; Bahari F; Culbertson B; Atanaki FF; Aditham AK; Kratz AF; Luck MI; Tian R; Goff SP; Montazeri H; Sabo Y; Ho DD; Chavez A
    Cell Host Microbe; 2022 Oct; 30(10):1354-1362.e6. PubMed ID: 36029764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 3CL
    Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
    Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
    Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor.
    Luo J; Wang W; Jiang H; Li W; Zeng P; Wang J; Zhou X; Zou X; Chen S; Wang Q; Zhang J; Li J
    Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(8):1257-1264. PubMed ID: 37357528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
    Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
    Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
    Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
    Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.